Back to top

oncology-screening: Archive

Ahan Chakraborty

Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?

Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.

SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change

Ahan Chakraborty

Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change RXRXNegative Net Change

Zacks Equity Research

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

MRKNegative Net Change BAYRYNegative Net Change MRUSNegative Net Change VRNAPositive Net Change